193 related articles for article (PubMed ID: 26979218)
21. End points in irritable bowel syndrome.
Mangel AW; Fehnel SE
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
[No Abstract] [Full Text] [Related]
22. ▼ Eluxadoline for IBS-D.
Drug Ther Bull; 2017 Aug; 55(8):90-93. PubMed ID: 28808081
[TBL] [Abstract][Full Text] [Related]
23. Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.
Chey WD; Dove LS; Andrae DA; Covington PS
Aliment Pharmacol Ther; 2017 May; 45(10):1319-1328. PubMed ID: 28326568
[TBL] [Abstract][Full Text] [Related]
24. IBS: Treating IBS with diarrhoea.
Dickson I
Nat Rev Gastroenterol Hepatol; 2016 Mar; 13(3):124. PubMed ID: 26837711
[No Abstract] [Full Text] [Related]
25. New treatment options for irritable bowel syndrome with predominant diarrhea.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):25-30. PubMed ID: 27875419
[TBL] [Abstract][Full Text] [Related]
26. Item-level assessment of the irritable bowel syndrome quality of life questionnaire in patients with diarrheal irritable bowel syndrome.
Andrae DA; Covington PS; Patrick DL
Clin Ther; 2014 May; 36(5):663-79. PubMed ID: 24813429
[TBL] [Abstract][Full Text] [Related]
27. FDA approves one drug for irritable bowel syndrome but suspends another.
Harv Womens Health Watch; 2008 Aug; 15(12):7. PubMed ID: 19115501
[No Abstract] [Full Text] [Related]
28. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
Gawron AJ; Bielefeldt K
Clin Gastroenterol Hepatol; 2018 Mar; 16(3):378-384.e2. PubMed ID: 28804032
[TBL] [Abstract][Full Text] [Related]
29. Green light from the FDA for new drug development in irritable bowel syndrome and functional dyspepsia.
Talley NJ
Am J Gastroenterol; 2009 Jun; 104(6):1339-41. PubMed ID: 19491845
[No Abstract] [Full Text] [Related]
30. Does the oral adsorbent AST-120 really improve symptoms for non-constipating irritable bowel syndrome?
Flood R; Donnellan C
Aliment Pharmacol Ther; 2012 Jan; 35(1):197-8; author reply 198-9. PubMed ID: 22150538
[No Abstract] [Full Text] [Related]
31. New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.
Corsetti M; Whorwell P
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):285-292. PubMed ID: 28276811
[TBL] [Abstract][Full Text] [Related]
32. The FDA and IBS drug development.
Mangel AW
Am J Gastroenterol; 2009 Dec; 104(12):3106; author reply 3106. PubMed ID: 19956135
[No Abstract] [Full Text] [Related]
33. Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?
Grover M; Camilleri M
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):960-2. PubMed ID: 24393804
[No Abstract] [Full Text] [Related]
34. Linaclotide for treatment of irritable bowel syndrome--the view of European regulators.
Berntgen M; Enzmann H; Schabel E; Prieto Yerro C; Gómez-Outes A; Salmonson T; Musaus J
Dig Liver Dis; 2013 Sep; 45(9):724-6. PubMed ID: 23701993
[No Abstract] [Full Text] [Related]
35. New drug approved for irritable bowel syndrome in women.
Mayo Clin Womens Healthsource; 2004 Feb; 8(2):3. PubMed ID: 14722489
[No Abstract] [Full Text] [Related]
36. Pathophysiology, Differential Diagnosis, and Treatment of Diabetic Diarrhea.
Selby A; Reichenbach ZW; Piech G; Friedenberg FK
Dig Dis Sci; 2019 Dec; 64(12):3385-3393. PubMed ID: 31541370
[No Abstract] [Full Text] [Related]
37. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Bleser S
Curr Med Res Opin; 2011 Mar; 27(3):503-12. PubMed ID: 21208139
[TBL] [Abstract][Full Text] [Related]
38. In brief: Pancreatitis with eluxadoline (Viberzi) in patients without a gallbladder.
Med Lett Drugs Ther; 2017 Apr; 59(1519):70. PubMed ID: 28419076
[No Abstract] [Full Text] [Related]
39. Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics.
Marbury TC; Berg JK; Dove LS; Covington PS
J Clin Pharmacol; 2017 Nov; 57(11):1454-1459. PubMed ID: 28719721
[No Abstract] [Full Text] [Related]
40. Editorial: colesevelam effects on faecal bile acids in IBS with diarrhoea.
Walters JR; Appleby RN
Aliment Pharmacol Ther; 2015 Apr; 41(7):696-7. PubMed ID: 25736144
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
